Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 12/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 12/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL3323309 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4GRIK1GRIK2HTR1D | |
| SCHEMBL3323019 | 0.93 | CHRNB2 (0.60) | CHRNB2CHRNA4GRIK1GRIK2 | |
| SCHEMBL3323013 | 0.93 | CHRNB2 (0.60) | CHRNB2CHRNA4GRIK1GRIK2 | |
| SCHEMBL3323305 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA4GRIK1GRIK2MASP2 | |
| SCHEMBL3326239 | 0.76 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL3326235 | 0.76 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL3326232 | 0.76 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL3325047 | 0.73 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL3325052 | 0.73 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| SCHEMBL620193 | 0.70 | CHRNB2 (0.56) | CHRNB2CHRNA4MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-12-28 | — | — | US | disclosed |
| US-7045538-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885GRIK1 509/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885GRIK1 300/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885GRIK1 509/4885 |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885GRIK1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.